JP Morgan Chase
INBX icon

JP Morgan Chase’s Inhibrx INBX Stock Holding History

JP Morgan Chase’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$295K Sell
4,932
-12,127
-71% -$900K ﹤0.01% 5289
2025
Q4 		$1.35M Buy
17,059
+12,230
+253% +$833K ﹤0.01% 4401
2025
Q3 		$163K Sell
4,829
-479
-9% -$11.8K ﹤0.01% 5627
2025
Q2 		$75.7K Sell
5,308
-1,089
-17% -$14.1K ﹤0.01% 5731
2025
Q1 		$89.5K Sell
6,397
-1,195
-16% -$16.2K ﹤0.01% 5626
2024
Q4 		$117K Buy
7,592
+2,457
+48% +$37.4K ﹤0.01% 5695
2024
Q3 		$80.4K Sell
5,135
-39,130
-88% -$550K ﹤0.01% 5790
2024
Q2 		$627K Buy
+44,265
New +$691K ﹤0.01% 4556

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase's INBX Position: Q1 2026 in Review

JP Morgan Chase reduced its Inhibrx (INBX) stake by 71% in Q1 2026, selling an estimated $900K and leaving 4,932 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #5289.

JP Morgan Chase first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.35M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • JP Morgan Chase held 4,932 shares of Inhibrx worth $295K as of Q1 2026.
  • JP Morgan Chase sold 12,127 Inhibrx shares in Q1 2026, an estimated $900K.
  • Inhibrx made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5289 holding.
  • JP Morgan Chase first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • JP Morgan Chase's Inhibrx position peaked at $1.35M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.